1. All Products
  2. H 75mg / R 150mg, tab., blister
Public Pricelist

H 75mg / R 150mg, tab., blister

https://medicalguidelines.msf.org/en/node/422
https://unicat.msf.org/cat/product/12078
STD DORAHRIF7T1

Valid Article

Former Code(s): -X DORARHFD1T7
6.2.5 - Antituberculosis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J04AM02
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

ISONIAZID (H) / RIFAMPICIN (R)

Therapeutic Action

Fixed-dose combination (FDC) of two bactericide antituberculosis drugs

Indications

Drug-Sensitive Tuberculosis (DS-TB)

Latent Tuberculosis Infection (LTI-TB)

Instructions for use

The dosage 50 mg / 75 mg is intended for paediatric use.

Blister packaging is the packaging of choice for antituberculosis medicines due to the unstable nature of some of them when exposed to higher temperatures and humidity.

Bulk packaging (hospital packs) should only be used in special circumstances or in case of unexpected problems in availability of the blister presentation.

The quantity to be ordered is calculated per tablet, not per blister.

Storage

Below 25ºC - Protect from sunlight - Protect from humidity